Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Exp Cell Res. 2011 May 15;317(9):1270-7. doi: 10.1016/j.yexcr.2011.02.005. Epub 2011 Feb 17.

BAFF inhibition: a new class of drugs for the treatment of autoimmunity.

Author information

  • 1Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA.

Abstract

BAFF (BLyS) and APRIL are TNF-like cytokines that support survival and differentiation of B cells. Recent studies have discovered a role for BAFF in augmenting both innate and adaptive immune responses as well as in collaborating with other inflammatory cytokines to promote the activation and differentiation of effector immune cells. BAFF is an important pathogenic factor in lupus mouse models and BAFF inhibition successfully delays disease onset in these mice, although the responsiveness to BAFF inhibition varies among different strains. These results have led to the development of inhibitors targeting BAFF and APRIL in humans. An anti-BAFF antibody has shown significant but modest efficacy in two Phase III clinical trials for moderately active SLE and other inhibitors are being developed or at early stages of clinical testing.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21333645
[PubMed - indexed for MEDLINE]
PMCID:
PMC3092018
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk